GlassScriptPhysician profile
Darren M Brenner
NPI 1003997875
$1,091,327.07
in general payments reported to CMS, 2019-2025
23 companies · $187K in 2025
The $187K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $221K · 2020: $48K · 2021: $151K · 2022: $166K · 2023: $153K · 2024: $166K · 2025: $187K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $230K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $116K · Consulting Fee: $112K · Travel and Lodging: $34K · Food and Beverage: $12K · Honoraria: $2,022.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $229,559.36 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $115,750.00 |
| Consulting Fee | $112,150.51 |
| Travel and Lodging | $33,524.30 |
| Food and Beverage | $12,333.20 |
| Honoraria | $2,022.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $487,223.96 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Abbvie INC. | $181,246.11 | 2021-2025 | Viberzi, Linzess |
| Ardelyx, INC. | $173,381.96 | 2022-2025 | Ibsrela |
| Allergan, INC. | $133,952.28 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34,734.56 | 2020-2023 | |
| Shire North American Group INC | $22,098.46 | 2019 | |
| Ironwood Pharmaceuticals, INC | $18,021.01 | 2019-2024 | Linzess |
| Alnylam Pharmaceuticals INC. | $10,904.38 | 2019-2022 | |
| Redhill Biopharma INC. | $9,183.74 | 2021-2022 | |
| Alfasigma USA, INC. | $6,585.04 | 2020 | |
| Dr.Reddy'S Laboratories,INC. | $5,050.51 | 2024 | |
| Exact Sciences Corporation | $2,438.61 | 2024 | Cologuard Collection Kit |
| Blueprint Medicines Corporation | $2,022.00 | 2024 | Ayvakit |
| Gi Supply, INC. | $2,000.00 | 2021 | |
| Mahana Therapeutics, INC. | $800.00 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vibrant Gastro, INC. | $758.56 | 2023 | Vibrant Starter Kit |
| Phathom Pharmaceuticals, INC. | $388.72 | 2024-2025 | Voquezna |
| Boston Scientific Corporation | $161.03 | 2022 | |
| Madrigal Pharmaceuticals | $142.72 | 2025 | Rezdiffra |
| Medtronic, INC. | $104.59 | 2024 | Manoscan, Gi Genius |
| Genzyme Corporation | $76.00 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $30.46 | 2019-2020 | |
| Coloplast Corp | $22.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darren Brenner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.